Loading...
Loading...
On Wednesday, Goldman Sachs upgraded shares of Teva Pharmaceutical Industries
TEVA from Sell to Neutral and raised the price target from $40 to $52.
Analyst Jami Rubin expects the “narrative around TEVA to change from concerns around a declining Copaxone franchise to growth and optionality in the underlying business.”
Rubin went on to propose changes management could make such as:
- Cut costs
- Narrow R&D focus
- Divest parts of business
The analyst said mergers & acquisitions are “one of the key drivers of sector performance” and believes Teva could “put about $10bn towards deal activity.”
Shares of Teva are up 1.3 percent to $50.57 in Wednesday's trading and up 26 percent year to date.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in